RAB Capital
VC Fund
London, United Kingdom
RAB Capital is a VC fund in London focused on Biotechnology and Manufacturing. RAB Capital plc is a privately owned hedge fund sponsor.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries RAB Capital invests in
Stages RAB Capital invests in
Countries RAB Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Venture - Series Unknown
- $4.2M–$7.8M
Investment Focus
Industry
- Biotechnology 2 (40%)
- Manufacturing 2 (40%)
- Energy 1 (20%)
- Medical 1 (20%)
- Chemical 1 (20%)
Stage
- Funding Round 2 (40%)
- Venture - Series Unknown 2 (40%)
- Seed 1 (20%)
Country
- United Kingdom 3 (60%)
- Ireland 1 (20%)
- United States 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Adam Grant
Team Member
|
Team Member | Total investments: 0 | Find email | |
| CEO | Total investments: 0 | Find email | ||
Philip Richards
Founder and Honorary President
|
Founder and Honorary President | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Power Roll Limited was established to develop and commercialise its highly innovative proprietary energy storage and energy generation technologies. Power Roll technologies exhibit a range of significant benefits and advantages over existing technologies such that it is likely that the technology can prove extremely disruptive across a wide rangeof applications and markets. Power Roll has a strong intellectual property portfolio, with 15 different patent families already established. These patent families are spread across all three technologies with five directly related to Energy Storage, nine related to Solar PV and one focusing on the nano-barrier technology. | $4.2M / Venture - Series Unknown / Feb 19, 2021 | ||
| Solvotrin Therapeutics Limited is a privately held pharmaceutical company focused on cardiovascular applications.Solvotrin’s business model is based on the development of new drugs that combine its unique patented prodrug platform with well established compounds in large markets. Its approach of chemically creating new chemical entities fromexisting compounds for synergistic benefits creates efficacy and safety advantages with significantly reduced development timeline and development risk.Solvotrin’s lead compound, ST0702 is a nicotinic acid prodrug, with significant efficacy and tolerability advantages over similar products for 54 dyslipidaemia. ST0701 is a bioactivated form of aspirin, which addresses the well documented gastrointestinal toxicity of aspirin. ST0703 is a ’nitro-aspirin‘ prodrug with dual antiplatelet effects and disease modifying potential.The company has a strong intellectual property underpin with patent protection at the highest, New Molecule level. Solvotrin’s strategy is to take its compounds to the end of Phase I and to partner the development and commercialisation phases with large pharmaceutical companies. | $7.8M / Venture - Series Unknown / Nov 02, 2020 | ||
| ETA's patented technology delivers advanced electric motors, power controllers and inverters to the Outdoor power equipment, Off highway, e-mobility, marine and HVAC sectors.Developed from over 15 years of research and expertise, our technology answers the unmet need for a market leading, efficient and inexpensive electric drive systemalternative to traditional internal combustion engines and some existing electric motors.Our game-changing electric motor topology offers advanced efficiency, high performance and a cost effective solution removing reliance on hydrocarbon fuel sources and rare-earth magnets whilst minimising manufacturing processes. | Seed / Sep 01, 2020 | ||
Viragen
|
Viragen, together with its subsidiaries, engages in the research, development, manufacture, and commercialization of therapeutic proteins for the treatment of cancers and viral diseases in humans. Its product and product candidate portfolio includes Multiferon, a human alpha interferon product that comprise multiple subtype alpha interferons forthe treatment of various infectious diseases and cancers; VG101 a therapeutic humanized monoclonal antibody targeting the treatment of malignant melanoma; and VG102 a therapeutic humanized antibody designed for the treatment of various solid tumors. The company also develops Avian Transgenics technology for production of human therapeutic proteins and antibodies. It operates in the United States, Scotland, and Sweden. The company was founded in 1979 and is headquartered in Plantation, Florida. | $3M / Apr 16, 2007 | |
| EnviroGene has been providing molecular diagnostic services to the water, contaminated land and oil and gas industry since 2004. They are experts at applying a 25-year old molecular biology technique known as the quantitative polymerase chain reaction (qPCR) to field studies. | $2M / Mar 26, 2007 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does RAB Capital invest in?
RAB Capital invests primarily in Biotechnology, Manufacturing and Energy startups, most often at Funding Round and Venture - Series Unknown stage. Most of the 5 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is RAB Capital's check size?
RAB Capital typically joins rounds of $4.2M–$7.8M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds RAB Capital participates in.
How do I contact RAB Capital?
Public channels for RAB Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at RAB Capital?
The team at RAB Capital includes Adam Grant (Team Member), Charles Kirwan-Taylor (CEO) and Philip Richards (Founder and Honorary President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
